SynthesisPharmacoEconomics2014
The health economics of bladder cancer: an updated review of the published literature.
Synthesis in PharmacoEconomics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 2 syntheses or guidelines pooled it, 206 citations in OpenAlex.
- Critical Appraisal of Decision Models Used for the Economic Evaluation of Bladder Cancer Screening and Diagnosis: A Systematic Review.PharmacoEconomics · 2023Pooled it
- Modifiable risk factors for the prevention of bladder cancer: a systematic review of meta-analyses.European journal of epidemiology · 2016Pooled it
- Bacillus Calmette-Guérin (BCG) in combination with PANVAC™ vs. BCG alone in adults with high-grade BCG-refractory non-muscle-invasive bladder cancer.Urologic oncology · 2025Trial
- Economic Considerations in the Management of Superficial Bladder Cancer.The Urologic clinics of North America · 2026Review
- A multi-modal approach for decision making in bladder cancer.Nature reviews. Urology · 2026Review
- Radiotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: Current Evidence and Future Directions.Current oncology (Toronto, Ont.) · 2026Review
- Contemporary Role for Blue Light Cystoscopy Across the Bladder Cancer Disease Spectrum.Current urology reports · 2026Review
- PD1-IL2v expands and induces effector CD8Journal of experimental & clinical cancer research : CR · 2026Article
- Urine-derived induced pluripotent stem cells for non-invasive diagnosis of bladder cancer.Journal of Cancer · 2026Review
- A Podcast on Real-World Evidence with Avelumab First-Line Maintenance and Treatment Sequencing in Locally Advanced or Metastatic Urothelial Carcinoma.Targeted oncology · 2025Article
- Diagnosis of early-stage bladder cancer via unprocessed urine samples at the point of care.Nature biomedical engineering · 2025Article
- A novel bladder cancer surveillance schedule using bladder Cx for patients on annual surveillance.BJUI compass · 2025Article
- Detection of Human Bladder Epithelial Cancerous Cells with Atomic Force Microscopy and Machine Learning.Cells · 2024Article
- Is There a Role for Surgery in the Treatment of Metastatic Urothelial Carcinoma?Journal of clinical medicine · 2024Review
- Magnetic 3D macroporous MOF oriented urinary exosome metabolomics for early diagnosis of bladder cancer.Journal of nanobiotechnology · 2024Article
- Economic Impact of Bladder Cancer in the USA.PharmacoEconomics - open · 2024Article
- Article
- Article
- Plasma-Derived Cell-Free DNA as a Biomarker for Early Detection, Prognostication, and Personalized Treatment of Urothelial Carcinoma.Journal of clinical medicine · 2024Review
- Plasma Levels of Pentraxin 3: A Potential Prognostic Biomarker in Urinary Bladder Cancer Patients.International journal of molecular sciences · 2024Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this paper is to provide a current view of the economic burden of bladder cancer, with a focus on the cost effectiveness of available interventions. This review updates a previous systematic review and includes 72 new papers published between 2000 and 2013. Bladder cancer continues to be one of the most common and expensive malignancies. The annual cost of bladder cancer in the USA during 2010 was $US4 billion and is expected to rise to $US5 billion by 2020. Ten years ago, urinary markers held the potential to lower treatment costs of bladder cancer. However, subsequent real-world experiments have demonstrated that further work is necessary to identify situations in which these technologies can be applied in a cost-effective manner. Adjunct cytology remains a part of diagnostic standard of care, but recent research suggests that it is not cost effective due to its low diagnostic yield. Analysis of intravesical chemotherapy after transurethral resection of bladder tumor (TURBT), neo-adjuvant therapy for cystectomy, and robot-assisted laparoscopic cystectomy suggests that these technologies are cost effective and should be implemented more widely for appropriate patients. The existing literature on the cost effectiveness of bladder cancer treatments has improved substantially since 2000. The body of work now includes many new models, registry analyses, and real-world studies. However, there is still a need for new implementation guidelines, new risk modeling tools, and a better understanding of the empirical burden of bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.